AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 51 min read$VSTM

Paterson Dan sold $8K of VSTM

Paterson Dan (President and CEO) sold 1,302 shares of Verastem, Inc. (VSTM) at $5.81 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Paterson Dan
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$VSTM
Neutral
high confidence
Mentioned
$VSTM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VSTMNeutralLow
01

Why it matters

The newest fact is the CEO’s Aug 3 open-market sale amount and price, filed on Aug 5. This can influence short-term sentiment but does not introduce new business or financial guidance.

02

Market read

Traders may note insider selling, but the 10b5-1 structure reduces interpretive weight versus an unplanned sale.

03

What to watch

The article provides only the sale details, not total insider ownership changes over time or any concurrent company-specific catalysts.

Relevance 2/10Novelty 3/10Timing: Filed Aug 5, covering an Aug 3 sale.

Background

The article is a SEC Form 4 insider transaction disclosure for Verastem, Inc. (VSTM).

Company-level read

Ticker impact

$VSTMNeutralHigh confidence
Context

Verastem CEO Paterson Dan filed a Form 4 open-market sale of 1,302 shares at $5.81 on Aug 3 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine 10b5-1 planned sale by the CEO, with no accompanying guidance, operational change, or transaction terms indicating new corporate risk.

Market effects

Sector

Minimal. Insider 10b5-1 sales are common and do not typically signal sector-wide changes.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • issuer
    Verastem, Inc.

    Company whose CEO insider sale is disclosed on Form 4.

  • insider
    Paterson Dan

    President and CEO who sold 1,302 shares at $5.81 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

VSTM insider trading history →

Related articles

OCT 28
$NVCRLowAI 8/10

Novocure partners with Verastem on pancreatic cancer trial

Novocure (NVCR) and Verastem Oncology (VSTM) partner to test Tumor Treating Fields therapy with VS-7375 for pancreatic cancer. Trial to start in 2027, focusing on safety and tolerability in 25 patients. Novocure will fund and manage the trial, while Verastem supplies the drug. The treatment aims to combine chemotherapy, VS-7375, and Tumor Treating Fields. Pancreatic cancer has a low survival rate and limited treatment options.

investing.com2 min
OCT 28
$NVCRLowAI 8/10

A planned trial will test electric-field therapy with chemotherapy and an experimental drug.

Novocure (NVCR) and Verastem Oncology plan a clinical trial to evaluate Tumor Treating Fields (TTFields) therapy with chemotherapy and Verastem’s experimental drug VS-7375 for locally advanced pancreatic cancer. The trial, expected to start in 2027, will assess safety and preliminary efficacy in about 25 patients. Novocure will manage and fund the trial, while Verastem will supply the drug. Both companies believe the combination could offer a new treatment approach for this challenging cancer.

stocktitan.net2 min
OCT 16
$VSTMHighAI 8/10

Wainwright reiterates Verastem stock rating on China trial data

H.C. Wainwright reiterated a Buy rating and $18.00 price target for Verastem (VSTM) after positive clinical trial data from China. The stock rose 10% last week to $9.23, up 46% in six months. GenFleet's data showed promising results for GFH375, the same molecule as Verastem's VS-7375, in colorectal and pancreatic cancer trials. Analysts maintain a strong buy consensus with targets ranging from $12 to $24.

investing.com2 min